Table 1.
Patient characteristics.
| Mycobacteriosis | Non-Mycobacteriosis | |
|---|---|---|
| Number | 16 | 26 |
| Age | 71 (58–76) | 63 (46–69) |
| Sex: Male | 8 (50%) | 11 (42%) |
| Serological test: positive | ||
| IGRA | 8 (50%) | 0 (0%) |
| anti-MAC antibody * | 5 (31%) | 1 (4%) |
| HRCT findings | ||
| Nodular shadow | 13 (81%) | 16 (62%) |
| Consolidation | 9 (56%) | 10 (38%) |
| Cavity formation | 3 (19%) | 3 (12%) |
| Bronchiectasis | 6 (38%) | 6 (23%) |
| LN enlargement | 3 (19%) | 10 (38%) |
| Final Diagnosis | ||
| TB | 7 (44%) | 0 (0%) |
| MAC infection | 7 (44%) | 0 (0%) |
| Follow-up † | 2 (12%) | 0 (0%) |
| Sarcoidosis | 0 (0%) | 10 (38%) |
| Other infectious disease | 0 (0%) | 4 (15%) |
| Interstitial lung disease | 0 (0%) | 3 (12%) |
| Other ‡ | 0 (0%) | 9 (35%) |
HRCT, high-resolution computed tomography; IGRA, interferon gamma releasing assay; LN, lymph node; MAC, Mycobacterium avium complex; TB, tuberculosis. * Anti-glycopeptidolipid core IgA antibody. † Mycobacteriosis group included the follow-up cases with a strong suspicion of mycobacteriosis strongly. ‡ These cases were diagnosed with bronchiectasis, cryptogenic organizing pneumonia, or diffuse panbronchiolitis. Some cases withdrew during follow-up.